Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab

Eur J Dermatol. 2017 Apr 1;27(2):205-208. doi: 10.1684/ejd.2016.2959.

Authors

Irene Russo¹, Giorgia Sacco¹, Stefano Frega², Valentina Polo², Giulia Pasello², Mauro Alaibac¹

Affiliations

¹ Unit of Dermatology, University of Padua, Padua, Italy.
² Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

PMID: 28251900
DOI: 10.1684/ejd.2016.2959

No abstract available

Publication types

Case Reports
Letter
Review

MeSH terms

Adenocarcinoma / therapy*
Adenocarcinoma of Lung
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Immunotherapy / adverse effects*
Lung Neoplasms / therapy*
Male
Middle Aged
Pemphigoid, Bullous / chemically induced*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
atezolizumab